Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06550024 · ClinicalTrials.gov registry record · NA
SakuraBead Used as Resorbable Embolic for Genicular Artery Embolization
A NA study of Osteoarthritis and Osteoarthritis, Knee, sponsored by CrannMed.
- Active
- Registry status
- NA
- Development phase
- 89
- Enrollment target
- 8
- Study locations
NCT06550024: Active NA study of Osteoarthritis and Osteoarthritis, Knee, sponsored by CrannMed.
NCT06550024 is a NA study of Osteoarthritis and Osteoarthritis, Knee that is active but no longer recruiting, run by CrannMed. The registered enrollment target is 89 participants, below the 817-participant average among 135 other Osteoarthritis trials with a reported enrollment target (89% lower). The trial reports 8 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06550024, a NA study of Osteoarthritis and Osteoarthritis, Knee, is active but no longer recruiting, sponsored by CrannMed.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 89 participants
- Enrollment target
- 8
- Study locations
Study Summary
An open label, prospective, two-arm, multicenter, randomized controlled trial comparing SakuraBead genicular artery embolization (GAE) with a control (corticosteroid injection).
Primary Outcome
Compare the proportion of responders\* (defined as ≥50% reduction in WOMAC Pain\*\* score and ≥2 point reduction in NRS\*\*\*) between the Investigational procedure and Control at 6 months. * Non-responders will include subjects experiencing device-related SAEs. \*\*Western Ontario and McMaster Universities Osteoarthritis Pain Index. Scale: 0-20, where a lower score represents a better outcome \*\*\*NRS: Numeric Rating Scale that measures pain from 0 (no pain) to 10 points (worst pain).
Conditions Studied
Interventions
- DRUG Corticosteroid Injection
- DEVICE SakuraBead Resorbable Microspheres
Study Locations (8)
Other
- Bokhua Memorial Cardiovascular Center - Tbilisi
- Royal Berkshire NHS Foundation Trust - Reading
Alabama
- University of Alabama Medicine - Birmingham
California
- Harbor UCLA Medical Center - Torrance
Florida
- Advanced Vascular Institute - Panama City
North Carolina
- IR Centers - Raleigh
Virginia
- IR Centers - Leesburg
Uzbekistan
- Nano Medical Clinic - Tashkent
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2024-11-28 |
| Est. Completion | 2028-10 |
| Phase | NA |
What the registry record for NCT06550024 still lists
NCT06550024 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 89 participants, a relatively small participant target, below the 817-participant average among 135 other Osteoarthritis trials with a reported enrollment target (89% lower).
The record links to 6 conditions, with Osteoarthritis appearing as the primary indexed condition, and to 2 interventions - of which Corticosteroid Injection is the first listed.
NCT06550024 lists 8 locations in 7 states (Other, Alabama, California).
Frequently Asked Questions
What is clinical trial NCT06550024 about?
NCT06550024 is a clinical study titled "SakuraBead Used as Resorbable Embolic for Genicular Artery Embolization". An open label, prospective, two-arm, multicenter, randomized controlled trial comparing SakuraBead genicular artery embolization (GAE) with a control (corticosteroid injection).
What is the current status of trial NCT06550024?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 89 participants. The study started on 2024-11-28. Estimated completion is 2028-10.
What conditions does trial NCT06550024 study?
This clinical trial studies the following conditions: Osteoarthritis, Osteoarthritis, Knee, Arthritis, Musculoskeletal Diseases, Rheumatic Diseases.
What interventions are being tested in trial NCT06550024?
The interventions under investigation include: Corticosteroid Injection (DRUG), SakuraBead Resorbable Microspheres (DEVICE).
Who is sponsoring clinical trial NCT06550024?
This trial is sponsored by CrannMed, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06550024 being conducted?
This trial has 8 study locations across Alabama, California, Florida, North Carolina, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoarthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06550024's enrollment target sits among peer trials
89 93rd of 135 higher than 42 of 135 other Osteoarthritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Osteoarthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
EMPHASYS Cup Positioning in THA With Non-Invasive Navigation (Velys Hip Navigation (VHN))
RECRUITING · NA
-
The PROACTIVE Study for Black Elders
RECRUITING · NA
-
Trans-arterial Embolization for the Treatment of Facet Pain Due to Facet Arthropathy
RECRUITING · NA
-
Dose Response of Exercise for Arthritis Management
RECRUITING · NA
-
Conversations in Health Literacy Using AI Technology for Osteoarthritis Patients
RECRUITING · NA
-
Activating SilverSneakers Benefits for Seniors With Osteoarthritis
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03682289 · 89 participants · Phase 2
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
- NCT04787939 · 89 participants · NA
Early Feeding After Oral Cavity Reconstruction
- NCT05480449 · 89 participants · Phase 1
Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)
- NCT05604131 · 89 participants · Phase 2
Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI